Bisphosphonate associated osteonecrosis of the jaw

摘要: In 2003, the first reports describing osteonecrosis of jaw (ONJ) in patients receiving bisphosphonates (BP) were published. These cases occurred with cancer high-dose intravenous BP; however, 5% osteoporosis low-dose bisphosphonate therapy. We present results a systematic review incidence, risk factors, diagnosis, prevention, and treatment BP associated ONJ. conducted comprehensive literature search for relevant studies on ONJ oncology published before February 2008.All selected articles sorted by area focus. Data each abstracted 2 independent reviewers. The showed that diagnosis is made clinically. Prospective data evaluating incidence etiologic factors are very limited. BP, appears to be dependent dose duration therapy, an estimated 1%-12% at 36 months exposure. patients, it rare, < 1 case per 100,000 person-years general population not known. Currently, there insufficient evidence confirm causal link between use patient concluded therapy primarily population. Prevention strategies currently based expert opinion focus maintaining good oral hygiene conservative surgical intervention.